Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Critical Path Institute’s New Business Model: An Interview With CEO Compton

Executive Summary

After six months on the job, Carolyn Compton, the institute’s new chief executive, has overhauled the funding rules to allow fees from big pharma to cover overhead as government funding dries up. Successor to founder Raymond Woosley, who retired last year, Compton shares her vision for securing the institute’s finances for the future amid tough economic times.

You may also be interested in...



Europe To Drive Global R&D Collaborations With Pharma Companies

Alzheimer’s disease research could be a beneficiary of Europe’s plan to include more non-EU partners in its new science funding program, Horizon 2020, and a new version of its public-private partnership with the pharmaceutical industry, the Innovative Medicines Initiative.

FDA’s Data Format Standards Approaching Cost-Benefit Analysis Stage

The agency sets a meeting for November and wants comments in advance on potential candidates for a format that will reduce the need for data integration steps between its various systems.

Critical Path Institute Seeks "Respected, Well Networked" CEO As Woosley Plans Retirement

Board member Bob Assenzo will lead a search committee to find a replacement for CPI's founding force, Raymond Woosley, who will step down next January.

Related Content

Topics

UsernamePublicRestriction

Register

PS054746

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel